Bionime Showcases RIGHTEST iFree 2 CGM at ATTD 2026, Highlighting Precision and Patient Comfort
Barcelona, Spain — At ATTD 2026, Bionime is drawing significant attention with the presentation of its latest innovation, the RIGHTEST iFree 2 Continuous Glucose Monitoring (CGM) system. Positioned at the forefront of diabetes care technology, the company emphasizes a clear message: in an era of increasingly “smart” devices, true value lies in precision, reliability, and user comfort.
The RIGHTEST iFree 2 CGM reflects Bionime’s commitment to delivering accurate glucose readings that healthcare professionals and patients can trust, while ensuring a seamless and comfortable user experience that integrates effortlessly into daily life.
The company’s booth (#09) has seen strong engagement from global partners, with a full house of attendees participating in dynamic B2B discussions. These conversations center not only on the CGM system itself but also on Bionime’s broader “Diabetes Care Ecosystem,” which aims to connect devices, data, and care pathways into a scalable and efficient solution.
“Precision meets scalability” has become a defining theme of Bionime’s presence at ATTD 2026, as the company showcases how its technologies can support both individual patient needs and large-scale healthcare systems.
With growing interest from international stakeholders, Bionime invites all attendees in Barcelona to visit Booth #09 and discover why the company is emerging as a trusted partner in advancing diabetes management.